ORIC Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc.

Biotechnology Research

South San Francisco, California 4,999 followers

Overcoming Resistance In Cancer

About us

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Website
https://oricpharma.com/
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
South San Francisco, California
Type
Public Company
Founded
2014
Specialties
Cancer Resistance, Immunotherapy, and Oncology

Locations

  • Primary

    240 E Grand Ave

    2nd Floor

    South San Francisco, California 94080, US

    Get directions
  • 12265 El Camino Real

    Suite 370

    San Diego , CA 92130, US

    Get directions

Employees at ORIC Pharmaceuticals Inc.

Updates

Similar pages

Browse jobs

Funding

ORIC Pharmaceuticals Inc. 7 total rounds

Last Round

Post IPO equity

US$ 125.0M

See more info on crunchbase